

PCL Department Publications - 2001

"A,B"

Dell CA, Likhodii SS, Musa K, Ryan MA, **Burnham WM**, Cunnane SC: Lipid and fatty acid profiles in rats consuming different high-fat ketogenic diets. *Lipids* 36: 373-378 (2001).

Edwards HE, Mo V, **Burnham WM**, MacLusky NJ: Gonadectomy unmasks an inhibitory effect of progesterone on amygdala kindling in male rats. *Brain Res.* 889: 260-263 (2001).

Edwards HE, **Burnham WM**: The impact of corticosteroids on the developing animal. *Pediatr Res.* 50: 433-440 (2001).

Francis J, Jung BP, Zhang G, Cheng J, Ho W, **Burnham WM**, Eubanks JH: Perforant pathway kindling transiently induces the mRNA expression of GABA-B receptors subtypes R1A and R2 in the adult rat hippocampus. *Brain Res Molec Brain Res.* 91: 159-162 (2001).

Busto UE, Sproule BA, Knight K, Herrmann N: Use of prescription and nonprescription hypnotics in a Canadian elderly population. *Can J Clin Pharmacol.* 8(4):213-21 (2001).

Kilicarslan T, Haining RL, Rettie AE, **Busto U**, Tyndale RF, Sellers EM: Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. *Drug Metab Dispos.* 29:460-5 (2001).

Naranjo CA, Tremblay LK, **Busto UE**: The role of the brain reward system in depression. *Prog Neuropsychopharmacol Biol Psychiatry.* 25(4):781-823 (2001).

"C"

Carmichael FJ: Recent developments in hemoglobin-based oxygen carriers--an update on clinical trials. *Transfus Apheresis Sci.* 24(1):17-21 (2001).

Cray SH, Crawford MW, Khayyam N, **Carmichael FJ**: Effects of hypoxia and isoflurane on liver blood flow: the role of adenosine. *Br J Anaesth.* 86(3):425-7 (2001).

Thomas ML, Crawford MW, Shams M, Gow R, **Carmichael FJ**: The effect of magnesium deficiency on volatile anaesthetic requirement in the rat: the role of central noradrenergic neuronal activity. *Magnes Res.* 14(3):195-201 (2001).

"D,E"

DaSilva JN, Burrow TE, Wilson AA, Houle S: N-[11/13C]methylation versus O-[11/13C]methylation using [11/13C]methyl iodide or [11/13C]methyl triflate in molecules containing both amino and phenol catechol groups. *J Label Compd Radiopharm.* 44: S983-S985 (2001).

DaSilva JN, Lourenco CM, Wilson AA, Houle S: Synthesis of the phosphodiesterase-4 inhibitors [11C] Ro 20-1724, R-, R/S- and S-[11C] rolipram. *J Label Compd Radiopharm.* 44: 373-384 (2001).

Lourenco CM, Houle S, Wilson AA, DaSilva JN: Characterization of r-(11)[C]rolipram for PET imaging of phosphodiesterase-4: in vitro binding, metabolism, and dosimetry studies in rats. *Nucl Med Biol.* 28: 347-358 (2001).

Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, **DaSilva J**, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH: The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F] setoperone PET imaging study. *Am J Psychiatry* 158: 78-85 (2001).

Wilson AA, Jin L, Garcia A, **DaSilva JN**, Houle S: An admonition when measuring the lipophilicity of radiotracers using counting techniques. *Appl Radiat Isot.* 54: 203-208 (2001).

Wilson AA, Jin L, Garcia A, **DaSilva JN**, Houle S: Carbon-11 labelled cholecystokinin B antagonists: radiosynthesis and evaluation in rats. *Life Sci.* 68: 1223-1230 (2001).

Atkins DL, **Dorian P**, Gonzalez ER, Gorgels AP, Kudenchuk PJ, Lurie KG, Morley PT, Robertson C, Samson RA, Silka MJ, Singh BN: Treatment of tachyarrhythmias. *Ann Emerg Med.* 37(4 Suppl): S91-109 (2001).

Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, Sheldon R, Talajic M, **Dorian P**, Newman D: New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. *Circulation* 103: 2365-2370 (2001).

Lee DS, **Dorian P**, Downar E, Burns M, Yeo EL, Gold WL, Paquette M, Lau W, Newman DM: Thrombogenicity of radiofrequency ablation procedures: what factors influence thrombin generation? *Eurospace* 3: 195-200 (2001).

Pinter A, **Dorian P**: Intravenous antiarrhythmic agents. *Curr Opin Cardiol.* 16: 17-22 (2001).

Qi X, Varma P, Newman D, Dorian P: Gap junction blockers decrease defibrillation thresholds without changes in ventricular refractoriness in isolated rabbit hearts. *Circulation* 104: 1544-1549 (2001).

Savelieva I, Paquette M, **Dorian P**, Luderitz B, Camm AJ: Quality of life in patients with silent atrial fibrillation. *Heart* 85: 216-217 (2001).

Verma A, Newman D, Geist M, Greenhut S, Laslop J, DeBellis L, Freeman MR, **Dorian P**: Effects of rhythm regularization and rate control in improving left ventricular function in atrial fibrillation patients undergoing atrioventricular nodal ablation. *Can J Cardiol.* 17: 437-445 (2001).

Tothfalusi L, **Endrenyi L**: Evaluation of some properties of individual bioequivalence (IBE) from replicate-design studies. *Int J Clin Pharmacol Ther.* 39: 162-166 (2001).

Tothfalusi L, **Endrenyi L**, Midha KK, Rawson MJ, Hubbard JW: Evaluation of the bioequivalence of highly-variable drugs and drug products. *Pharm Res.* 18: 728-733 (2001).

"F,G"

Clements MK, McDonald TP, Wang R, Xie G, O'Dowd BF, **George SR**, Austin CP, Liu Q: FMRamide-related neuropeptides are agonists of the orphan G-protein-coupled receptor GPR54. *Biochem Biophys Res Commun.* 284: 1189-1193 (2001).

El-Ghundi M, O'Dowd BF, **George SR**: Prolonged fear responses in mice lacking dopamine D1 receptor. *Brain Res.* 892: 86-93 (2001).

Lamey M, Thompson M, Varghese G, Chi H, Sawzdargo M, **George SR**, O'Dowd BF: Distinct residues in the carboxyl tail mediate agonist induced desensitization and internalization of the human dopamine D1 receptor. *J Biol Chem.* Dec 31 (2001).

Lee DK, Nguyen T, Lynch KR, Cheng R, Vanti WB, Arkhitko O, Lewis T, Evans JF, **George SR**, O'Dowd BF: Discovery and mapping of ten novel G protein-coupled receptor genes. *Gene* 275: 83-91 (2001).

Lee DK, **George SR**, Evans JF, Lynch KR, O'Dowd BF: Orphan G protein-coupled receptors in the CNS. *Curr Opin Pharmacol.* 1: 31-39 (2001).

Lee DK, **George SR**, Cheng R, Nguyen T, Liu Y, Brown M, Lynch KR, O'Dowd BF: Identification of four novel human G protein-coupled receptors expressed in the brain. *Brain Res Mol Brain Res.* 86: 13-22 (2001).

Nguyen T, Shapiro DA, **George SR**, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, O'Dowd BF: Discovery of a novel member of the histamine receptor family. *Mol Pharmacol.* 59: 427-433 (2001).

Salmena L, Lam V, McPherson JP, **Goldenberg GJ**: Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase II alpha expression. *Biochem. Pharmacol.* 61: 795-802 (2001).

Rodrigues-Lima F, Delomenie C, Goodfellow GH, **Grant DM**, Dupret JM: Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active-site loop. *Biochem J.* 356(Pt 2): 327-334 (2001).

Vaziri SA, Hughes NC, Sampson H, Darlington G, Jewett MA, **Grant DM**: Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects. *Pharmacogenetics* 11: 7-20 (2001).

"H"

Wong JK, **Haas DA**, Hu JW: Local anesthesia does not block mustard-oil-induced temporomandibular inflammation. *Anesth Analg.* 92: 1035-1040 (2001).

Naples MA, **Hampson DR**: Pharmacological profiles of the metabotropic glutamate receptor ligands. *Neuropharmacology* 40: 170-177 (2001).

Park P, Sum CS, **Hampson DR**, Van Tol HH, Wells JW: Nature of the oligomers formed by muscarinic m2 acetylcholine receptors in Sf9 cells. *Eur J Pharmacol.* 421: 11-22 (2001).

Sansig G, Bushell TJ, Clarke VR, Rozov A, Burnashev N, Portet C, Gasparini F, Schmutz M, Klebs K, Shigemoto R, Flor PJ, Kuhn R, Knoepfel T, Schroeder M, **Hampson DR**, Collett VJ, Zhang C, Duvoisin RM, Collingridge GL, Van Der Putten H: Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7. *J Neurosci.* 21: 8734-8745 (2001).

Wong CG, Sherer SW, Snead OC 3rd, **Hampson DR**: Localization of the human mGluR4 gene within an epilepsy susceptibility locus(1). *Brain Res Mol Brain Res.* 87: 109-116 (2001).

Smith GB, **Harper PA**, Wong JM, Lam MS, Reid KR, Petsikas D, Massey TE: Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphism. *Cancer Epidemiol Biomarkers Prev.* 10(8):839-53 (2001).

Wolff S, **Harper PA**, Wong JM, Mostert V, Wang Y, Abel J: Cell-specific regulation of human aryl hydrocarbon receptor expression by transforming growth factor-beta(1). *Mol Pharmacol.* 59(4):716-24 (2001).

Wong JM, Okey AB, **Harper PA**: Human aryl hydrocarbon receptor polymorphisms that result in loss of CYP1A1 induction. *Biochem Biophys Res Commun.* 288(4):990-6 (2001).

Wong JM, **Harper PA**, Meyer UA, Bock KW, Morike K, Lagueux J, Ayotte P, Tyndale RF, Sellers EM, Manchester DK, Okey AB: Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. *Pharmacogenetics* 11(1):85-94 (2001).

"I,J"

Ishii M, XU BQ, Ding LR, Fischer NE, **Inaba T**: Interaction of plasma proteins with Cytochromes P450 mediated metabolic reactions: Inhibition by human serum albumin and alpha-globulins of the debrisoquine 4-hydroxylation (CYP2D) in liver microsomes of human, hamster and rat. *Tox Lett.* 119: 219-225 (2001).

Ito S: Transplacental treatment of fetal tachycardia: implications of drug transporting proteins in placenta. *Sem Perinatol.* 25: 196-201 (2001).

Ito S: Drug use during pregnancy and lactation. In: I. Yoshida (ed). Pediatric Drug Therapy Handbook. Chuugai Publishing (Tokyo). First ed. pp. 32-36 (2001).

Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, **Ito S**, Buncic RJ: Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. *Lancet* 358: 813-814 (2001).

Stiskal J, Kulin N, Koren G, Ho T, **Ito S**: Neonatal paroxetine withdrawal syndrome. *Arch Dis Child* 84: F134-F135 (2001).

Taddio A, Ito S: Drug use during lactation-a review. In: G. Koren (ed). Maternal Fetal Toxicology: A Clinician's Guide. Marcel Dekker, NY, 3rd ed. pp. 177-232 (2001).

"K"

Kalant H: Medicinal use of cannabis: History and current status. *Pain Res Manag.* 6: 80-91 (2001).

Kalant H: The pharmacology and toxicology of Aecstasy@ (MDMA) and related drugs. *CMAJ*. 165: 917-928 (2001).

Kalant, H: Not "Is it treatment?" but "Does it work?" *Addiction* 96: 560-562 (2001).

Kalant H, Poikolainen K: Taking money from the drinks industry does not necessarily set up a conflict. *Addiction* 96: 1511 (2001).

Leson G, Pless P, Grotenhermen F, **Kalant H, ElSohly MA:** Evaluating the impact of hemp food consumption on workplace drug tests. *J Anal Toxicol*. 25: 691-698 (2001).

Suwaki H, **Kalant H, Higuchi S, Crabbe JC, Ohkuma S, Katsura M, Yoshimura M, Stewart RC, Li TK, Weiss F:** Recent research on alcohol tolerance and dependence. *Alcohol Clin Exp Res*. 25(5 Suppl ISBRA): 189S-196S (2001).

Bertilsson L. **Kalow W:** Interethnic differences in drug disposition and effects. In: Pacifici GM, Pelkonen O, (eds). *Interindividual variability in human drug metabolism*. Taylor & Francis Inc., New York, 2001 Chapter 2. pp. 15-74.

Kalow W: Pharmacogenetics, pharmacogenomics, and pharmacobiology. *Clin Pharmacol Ther*. 70: 1-4 (2001).

Kalow W: Pharmacogenetics in perspective. *Drug Metab Dispos*. 29(4 Pt 2): 468-470 (2001).

Kalow W: Perspectives in pharmacogenetics. *Arch Pathol Lab Med*. 125: 77-80 (2001).

Kalow W: Historical aspects of pharmacogenetics. In: Pharmacogenomics. W. Kalow, U.A. Meyer, R. Tyndale (eds). Marcel Dekker Inc., New York, 2001 pp. 1-9.

Kalow W: Interethnic Differences in Drug Response. In: Pharmacogenomics. Kalow W, Meyer R, Tyndale R, (eds). Marcel Dekker Inc., New York, 2001 pp. 109-134.

Kalow W, Motulsky AG: General conclusions and future directions. In: Pharmacogenomics. Kalow W, Meyer WA, Tyndale R, (eds). Marcel Dekker Inc., New York, 2001 pp.389-395.

Kalow W, Grant DM: Pharmacogenetics. In: Scriver CR, Beaudet AL, Sly WS, Valle D, (eds). *The Metabolic & Molecular Bases of Inherited Disease* 8th Edition. B. Childs, K.W. Kinzler, B. Vogelstein (Associate eds). McGraw-Hill 2001 pp. 225-255.

Kalow W: Genetic factors that cause variability in human drug metabolism. In: *Interindividual variability in human drug metabolism*. G.M. Pacifici, O. Pelkonen (eds). Taylor & Francis Inc., New York, 2001 Chapter I. pp. 1-14.

Ozdemir V, Shear NH, **Kalow W**: What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? *Drug Safety* 24: 75-85 (2001).

Ozdemir V, **Kalow W**, Okey AB, Lam MS, Albers LJ, Reist C, Fourie J, Posner P, Collins EJ, Roy R: Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C--> A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. *J Clin Psychopharmacol.* 21: 603-607 (2001).

Ozdemir V, **Kalow W**, Posner P, Collins EJ, Kennedy JL, Tang BK, Albers LJ, Reist C, Roy R, Walkes W, Afra P: CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. *J Clin Psychopharmacol.* 21: 398-407 (2001).

Sy SK, Tang BK, Pastrakuljic A, Roberts EA, **Kalow W**: Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine. *Eur J Clin Pharmacol.* 57: 377-386 (2001).

Kalow W, Ozdemir V, Tothfalusi L: Multigenic traits and risk assessment in pharmacology: a population approach. *Pharmacogenomics J (letter)* 1: 234-235 (2001).

Cookson ST, Carballo M, Nolan CM, **Keystone JS**, Jong EC: Migrating populations--a closer view of who, why, and so what. *Emerg Infect Dis.* 7(3 Suppl):551 (2001).

Correia JD, Shafer RT, Patel V, Kain KC, Tessier D, MacPherson D, **Keystone JS**: Blood and body fluid exposure as a health risk for international travelers. *J Travel Med.* 8(5):263-6 (2001).

Kain KC, Shanks GD, **Keystone JS**: Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. *Clin Infect Dis.* 33(2):226-34 (2001).

Kain KC, MacPherson DW, Kelton T, **Keystone JS**, Mendelson J, MacLean JD: Malaria deaths in visitors to Canada and in Canadian travellers: a case series. *CMAJ.* 164(5):654-9 (2001).

Keystone JS, Kozarsky PE, Freedman DO: Internet and computer-based resources for travel medicine practitioners. *Clin Infect Dis.* 32(5):757-65 (2001).

Shanks GD, Kain KC, **Keystone JS**: Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. *Clin Infect Dis.* 33(3):381-5 (2001).

Furukawa Y, Graf WD, Wong H, Shimadzu M, **Kish SJ**: Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. *Neurology* 56: 260-263 (2001).

Kalasinsky KS, Bosy TZ, Schmunk GA, Reiber G, Anthony RM, Furukawa Y, Guttman M, **Kish SJ**: Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. *Forensic Sci Int.* 116: 163-169 (2001).

Kalasinsky KS, Dixon MM, Schmunk GA, **Kish SJ**: Blood, brain, and hair GHB concentrations following fatal ingestion. *J Forensic Sci.* 46: 728-730 (2001).

Kish SJ, Kalasinsky KS, Schmunk G, Furukawa Y, Guttman M, Ang L: Dopaminergic changes in human brain following acute exposure to gamma-hydroxybutyrate. *Neurology* 56: 1602-1603 (2001).

Kish SJ, Kalasinsky KS, Derkach P, Schmunk GA, Guttman M, Ang L, Adams V, Furukawa Y, Haycock JW: Striatal dopaminergic and serotonergic markers in human heroin users. *Neuropsychopharmacology* 24: 561-567 (2001).

Ross BM, Mamalias N, Moszczynska A, Rajput AH, **Kish SJ**: Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease. *Neuroscience* 102: 899-904 (2001).

Tong J, Ross BM, Sherwin AL, **Kish SJ**: Dopamine D1-stimulated adenylyl cyclase activity in cerebral cortex of autopsied human brain. *Neurochem Int.* 39: 117-125 (2001).

Addis A, Moretti ME, Ahmed Syed F, Einarson TR, **Koren G**: Fetal effects of cocaine: an updated meta-analysis. *Reprod Toxicol.* 15: 341-69 (2001).

Aleksa K, Woodland C, **Koren G**: Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies. *Pediatr Nephrol.* 16: 1153-1158 (2001).

Atanackovic G, Navioz Y, Moretti ME, **Koren G**: The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. *J Clin Pharmacol.* 41: 842-5 (2001).

Bailey B, Lalkin A, Kapur BM, **Koren G**: Is chronic poisoning with acetaminophen in children a frequent occurrence in Toronto? *Can J Clin Pharmacol.* 8: 96-101 (2001).

Bar-Oz B, Berkovitch M, Ford-Jones L, **Koren G**: Congenital cytomegalovirus infection. Is there a breakthrough? *Can Fam Physician* 47:1179-81 (2001).

Boskovic R, Klein J, Woodland C, Karaskov T, **Koren G**: The role of the placenta in variability of fetal exposure to cocaine and cannabinoids: a twin study. *Can J Physiol Pharmacol*.79: 942-945 (2001).

Carver V, Coyle B, **Koren G**, Lavigne S, Martinez L, Robertson J, Polifka J, Stepanuk K: A call for action-prevention of fetal exposure to isotretinoin, a position paper by the organization of teratology information services public affairs committee. *Reprod Toxicol*. 15: 729 (2001).

Costei AM, King SM, **Koren G**: Update on perinatal HIV. *Can Fam Physician* 47: 2221-2222 (2001).

Einarson A, Schuhaiber S, **Koren G**: Effects of antibacterials on the unborn child: what is known and how should this influence prescribing. *Paediatr Drugs* 3: 803-816 (2001).

Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, Mastoiacovo P, Addis A, Matsui D, Schuler L, Einarson TR, **Koren G**: Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. *Am J Psychiatry* 158: 1728-30 (2001).

Fouladi M, Stempak D, Gammon J, Klein J, Grant R, Greenberg ML, **Koren G**, Baruchel S: Phase I trial of a twice-daily regiment of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. *Cancer* 92: 914-23 (2001).

Gallo M, **Koren G**: Can herbal products be used safely during pregnancy? Focus on echinacea. *Can Fam Physician* 47: 1727-8 (2001).

Gesundheit B, Cividalli G, Freeman A, Yatziv S, **Koren G**, Baruchel S: Cyclosporin A in the treatment of refractory immune thrombocytopenia purpura in children. *Eur J Haematol*. 66:347-51 (2001).

Hard ML, Raha S, Spino M, Robinson BH, **Koren G**: Impairment of pyruvate dehydrogenase activity by acetaldehyde. *Alcohol* 25: 1-8 (2001).

Hard ML, Einarson TR, **Koren G**: The role of acetaldehyde in pregnancy outcome after prenatal alcohol exposure. *Ther Drug Monit*. 23: 427-34 (2001).

Ho E, Karimi-Tabesh L, **Koren G**: Characteristics of pregnant women who use Ecstasy (3,4-methylenedioxymethamphetamine). *Neurotoxicol Teratol*. 23: 561-567 (2001).

Ho E, Collantes A, Kapur BM, Moretti M, **Koren G**: Alcohol and breastfeeding: calculation of time to zero level in milk. *Biol Neonate* 80: 219-22 (2001).

Jasper JD, Goel R, Einarson A, Gallo M, **Koren G**: Effects of framing on teratogenic risk perception in pregnant women. *Lancet* 358: 1237-1238 (2001).

Kapur B, **Koren G**: Motherisk alert: Folic acid fortification of flour--three years later. *Can J Clin Pharmacol*. 8: 91-2 (2001).

Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, **Koren G**, Ito S, Buncic RJ: Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. *Lancet* 358: 813-4 (2001).

Koren G: Maternal obesity and risk of neural tube defects. *Can Fam Physician* 47: 1385-1387 (2001).

Koren G: Nicotine replacement therapy during pregnancy. *Can Fam Physician* 47: 1971-1972 (2001).

Kozer E, **Koren G**: Management of paracetamol overdose: current controversies. *Drug Safety* 24:503-12 (2001).

Kramer MS, Goulet L, Lydon J, Seguin L, McNamara H, Dassa C, Platt RW, Chen MF, Gauthier H, Genest J, Kahn S, Libman M, Rozen R, Masse A, Miner L, Asselin G, Benjamin A, Klein J, **Koren G**: Socio-economic disparities in preterm birth: causal pathways and mechanisms. *Paediatr Perinat Epidemiol*. 15 (suppl 2): 104-23 (2001).

Nikfar S, **Koren G**: Managing hypothyroidism during pregnancy. *Can Fam Physician* 47: 1555-6 (2001).

Nulman I, Rovet J, Greenbaum R, Loebstein M, Wolpin J, Pace-Asciak P, **Koren G**: Neurodevelopment of adopted children exposed in utero to cocaine: The Toronto Adoption Study. *Clin Invest Med*. 24:129-37 (2001).

Nulman I, Laslo D, Fried S, Uleryk E, Lishner M, **Koren G**: Neurodevelopment of children exposed in utero to treatment of maternal malignancy. *Br J Cancer* 85: 1611-1618 (2001).

Pole M, **Koren G**: Finasteride. Does it affect spermatogenesis and pregnancy? *Can Fam Physician* 47: 2469-2470 (2001).

Stempak D, Dallas S, Klein J, Bendayan R, **Koren G**, Baruchel S: Glutathione stability in whole blood: effects of various deproteinizing acids. *Ther Drug Monit* 23: 542-9 (2001).

Till C, **Koren G**, Rovet JF: Prenatal exposure to organic solvents and child neurobehavioral performance. *Neurotoxicol Teratol*. 23:235-45 (2001).

Till C, Westall CA, Rovet JF, **Koren G**: Effects of maternal occupational exposure to organic solvents on offspring visual functioning: a prospective controlled study. *Teratology* 64:134-41 (2001).

Ursitti F, Klein J, Sellers E, **Koren G**: Use of hair analysis for confirmation of self-reported cocaine use in users with negative urine tests. *J Toxicol Clin Toxicol*. 39: 361-6 (2001).

Ursitti F, Klein J, **Koren G**: Confirmation of cocaine use during pregnancy: a critical review. *Ther Drug Monit.* 23: 347-53 (2001).

"L"

Gold JL, Laxer DA, Dergal JM, **Lanctot KL**, Rochon PA: Herbal-drug therapy interactions: a focus on dementia. *Curr Opin Clin Nutr Metab Care* 4: 29-34 (2001).

Lanctot KL, Herrmann N, Mazzotta P: Role of serotonin in the behavioral and psychological symptoms of dementia. *J Neuropsychiatry Clin Neurosci.* 13: 5-21 (2001).

Rojas-Fernandez CH, **Lanctot KL**, Allen DD, MacKnight C: Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm? *Pharmacotherapy* 21: 74-102 (2001).

Le AD, Israel Y, Juzysch W, Quan B, Harding S: Genetic selection for high and low alcohol consumption in a limited-access paradigm. *Alcohol Clin Exp Res.* 25: 1613-1620 (2001).

Le AD, Kiianmaa K, Cunningham CL, Engel JA, Ericson M, Soderpalm B, Koob GF, Roberts AJ, Weiss F, Hyytia P, Janhunen S, Mikkola J, Backstrom P, Ponomarev I, Crabbe JC: Neurobiological processes in alcohol addiction. *Alcohol Clin Exp Res.* 25(5 Suppl ISBRA): 144S-151S (2001).

Chang A, **Li PP**, Warsh JJ: cAMP signal transduction abnormalities in the pathophysiology of mood disorders: contributions from postmortem brain studies. In: Belmaker RH, Agam G, Everall I, (eds.). The Post-mortem Brain in Psychiatric Research. Kluwer Academic Publishers, London, pp. 341-361 (2001).

Corson TW, **Li PP**, Kennedy JL, Macciardi F, Cooke RG, Parikh SV, Warsh JJ: Association analysis of G-protein beta 3 subunit gene with altered Ca(2+) homeostasis in bipolar disorder. *Mol Psychiat.* 6: 125-126 (2001).

Hua LV, Green M, Wong A, Warsh JJ, **Li PP**: Tetraspan protein CD151: a common target of mood stabilizing drugs? *Neuropsychopharmacology* 25: 729-736 (2001).

Hua LV, Green M, Warsh JJ, **Li PP**: Molecular cloning of a novel isoform of diphosphoinositol polyphosphate phosphohydrolase: a potential target of lithium therapy. *Neuropsychopharmacology.* 24: 640-651 (2001).

Yoon IS, **Li PP**, Siu KP, Kennedy JL, Cooke RG, Parikh SV, Warsh JJ: Altered IMPA2 gene expression and calcium homeostasis in bipolar disorder. *Mol Psychiat.* 6: 678-683 (2001).

Yoon IS, **Li PP**, Siu KP, Kennedy JL, Macciardi F, Cooke RG, Parikh SV, Warsh JJ: Altered TRPC7 gene expression in bipolar-I disorder. *Biol Psychiat.* 50: 620-626 (2001).

M''

Bai D, Zhu G, Pennefather P, Jackson MF, **MacDonald JF**, Orser BA: Distinct functional and pharmacological properties of tonic and quantal inhibitory postsynaptic currents mediated by gamma-aminobutyric acid (A) receptors in hippocampal neurons. *Mol Pharmacol.* 59: 814-824 (2001).

Erdeljan P, **MacDonald JF**, Matthews SG: Glucocorticoids and serotonin alter glucocorticoid receptor (GR) but not mineralocorticoid receptor (MR) mRNA levels in fetal mouse hippocampal neurons, in vitro. *Brain Res.* 896: 130-136 (2001).

Huang Y, Lu W, Ali DW, Pelkey KA, Pitcher GM, Lu YM, Aoto H, Roder JC, Sasaki T, Salter MW, **MacDonald JF**: CAKbeta/pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus. *Neuron* 29: 485-496 (2001).

Joo DT, Gong D, Sonner JM, Jia Z, **MacDonald JF**, Eger EI 2nd, Orser BA: Blockade of AMPA receptors and volatile anesthetics: reduced anesthetic requirements in GluR2 null mutant mice for loss of the righting reflex and antinociception but not minimum alveolar concentration. *Anesthesiology* 94: 478-488 (2001).

Lei S, **MacDonald JF**: Gadolinium reduces AMPA receptor desensitization and deactivation in hippocampal neurons. *J Neurophysiol.* 86: 173-182 (2001).

Lei S, Czerwinska E, Czerwinski W, Walsh MP, **MacDonald JF**: Regulation of NMDA receptor activity by F-actin and myosin light chain kinase. *J Neurosci.* 21: 8464-8472 (2001).

Lei S, Orser BA, Thatcher GR, Reynolds JN, **MacDonald JF**: Positive allosteric modulators of AMPA receptors reduce proton-induced receptor desensitization in rat hippocampal neurons. *J Neurophysiol.* 85: 2030-2038 (2001).

Lu W, Man H, Ju W, Trimble WS, **MacDonald JF**, Wang YT: Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. *Neuron* 29: 243-254 (2001).

MacDonald JF, Kotecha SA, Lu WY, Jackson MF: Convergence of PKC-dependent kinase signal cascades on NMDA receptors. *Curr Drug Targets* 2: 299-312 (2001).

Toong S, Xiong ZG, Zavorin SI, Bai D, Orser BA, Thatcher GR, Reynolds JN, **MacDonald JF**: Modulation of AMPA receptors by a novel organic nitrate. *Can J Physiol Pharmacol.* 79: 422-429 (2001).

Xiong ZG, Chu XP, **MacDonald JF**: Effect of lamotrigine on the Ca(2+)-sensing cation current in cultured hippocampal neurons. *J Neurophysiol.* 86: 2520-2526 (2001).

MacLeod SM: Prescription data. *CMAJ* 164: 1409 (2001).

Mayeenuddin LH, **Mitchell J**: Retinal phospholipase C from squid is a regulator of Gq α GTPase activity. *J Neurochem.* 78:1350-1358 (2001).

Mayeenuddin LH, **Mitchell J**: cDNA cloning and characterization of a novel squid rhodopsin kinase encoding multiple modular domains. *Vis Neurosci.* 18: 1-9. (2001).

Liu BA, Knowles SR, **Mittmann N**, Einarson T, Shear NH: Reporting of fatal adverse drug reactions. *Can J Clin Pharmacol.* 8: 84-88 (2001).

Dimitroulakos J, Ye L, Benzaquen M, **Moore MJ**, Kamel-Reid S, Freedman FH, Yeger HK, Penn LZ: Differential sensitivity of various pediatric cancers and squamous cell carcinomas to Lovastatin induced apoptosis: therapeutic implications. *Clin. Cancer Res.* 7: 158-167 (2001).

Dowling AJ, Panzarella T, Ernst DS, Neville AJ, **Moore MJ**, Tannock IF: A retrospective analysis of the relationship between changes in PSA, palliative response and survival following systemic treatment in a Canadian Randomized trial for hormone refractory prostate cancer. *Ann. Oncol.* 12: 773-778 (2001).

Knox JJ, **Moore MJ**: Treatment of hormone refractory prostate cancer. *Semin Urol Oncol.* 19: 202-11 (2001).

Li M, Firby P, Horn L, **Moore MJ**: Pharmacological determinants of 9-Aminocamptothecin cytotoxicity. *Clin. Cancer Res.* 7:168-174 (2001).

Moore MJ. Systemic therapy of advanced bladder cancer - What have we achieved? *J Evidence Based Oncol.* 2: 25-26 (2001).

Muzzammil T, **Moore MJ**, Ballinger JR. Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of p-glycoprotein function. *Br J Cancer* 84: 367-373 (2001)

"N"

Brosen K, **Naranjo CA**: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. *Eur Neuropsychopharmacol.* 11: 275-283 (2001).

Naranjo CA, Knoke DM: The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. *J Clin Psychiat.* 62 (Suppl 20): 18-25 (2001).

Naranjo CA, Tremblay LK, Busto UE: The role of the brain reward system in depression. *Prog Neuropsychopharmacol Biol Psychiat.* 25: 781-823 (2001).

Brown PJ, **Neuman MG**: Digestive Disease Week 2000 conference report: New treatments for chronic hepatitis C. *Can J Clin Pharmacol.* 8: 67-71 (2001).

Cameron RG, Blendis LM, **Neuman MG**: Accumulation of macrophages in primary sclerosing cholangitis. *Clin Biochem.* 34: 195-201 (2001).

Jacobson-Brown PM, **Neuman MG**: Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines. *Clin Biochem.* 34: 167-171 (2001).

Katz GG, Shear NH, Malkiewicz IM, Valentino K, **Neuman MG**: Signaling for ethanol-induced apoptosis and repair in vitro. *Clin Biochem.* 34: 219-227 (2001).

Krivoy N, Struminger L, Bendersky R, Avivi I, **Neuman M**, Pollack S: Riphampin-induced thrombocytopenia: Diagnosis by a Novel In Vitro Lymphocyte Toxicity Assay. *Isr Med Assoc J.* 3: 536-538 (2001).

Neuman MG, Shear NH, Jacobson-Brown PM, Katz GG, Neilson HK, Malkiewicz IM, Cameron RG, Abbott F: CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity. *Clin Biochem.* 34: 211-218 (2001).

Neuman MG, Blendis LM, Shear NH, Malkiewicz IM, Ibrahim A, Katz GG, Sapir D, Halpern Z, Brill S, Peretz H, Magazinik S, Konikoff FM: Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate. *Clin Biochem.* 34: 183-188 (2001).

Neuman MG, Benhamou JP, Malkiewicz IM, Akremi R, Shear NH, Asselah T, Ibrahim A, Boyer N, Martinot-Peignoux M, Jacobson-Brown P, Katz GG, Le Breton V, Le Guludec G,

Suneja A, Marcellin P: Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. *Clin Biochem.* 34: 173-182 (2001).

Popat A, Shear NH, Malkiewicz I, Stewart MJ, Steenkamp V, Thomson S, **Neuman MG**: The toxicity of Callilepis alureola, a South African traditional herbal medicine. *Clin Biochem.* 34: 229-236 (2001).

Neuman MG: Apoptosis in diseases of the liver. *Crit Rev Clin Lab Sci.* 38: 109-166 (2001).

Neuman MG, Brenner DA, Rehermann B, Taieb J, Chollet-Martin S, Cohard M, Garaud JJ, Poynard T, Katz GG, Cameron RG, Shear NH, Gao B, Takamatsu M, Yamauchi M, Ohata M, Saito S, Maeyama S, Uchikoshi T, Toda G, Kumagi T, Akbar SM, Abe M, Michitaka K, Horiike N, Onji M: Mechanisms of alcoholic liver disease: Cytokines. *Alcohol Clin Exp Res.* 25(5 Suppl ISBRA): 251S-253S (2001).

Kapur S, Barlow K, VanderSpek SC, Javanmard M, **Nobrega JN**: Drug-induced receptor occupancy: substantial differences in measurements made in vivo vs ex vivo. *Psychopharmacology* 157: 168-171 (2001).

Vallbacka JJ, **Nobrega JN**, Sefton MV: Tissue engineering as a platform for controlled release of therapeutic agents: implantation of microencapsulated dopamine producing cells in the brains of rats. *J Control Release* 72: 93-100 (2001).

"O"

Clements MK, McDonald TP, Wang R, Xie G, **O'Dowd BF**, George SR, Austin CP, Liu Q: FMRamide-related neuropeptides are agonists of the orphan G-protein-coupled receptor GPR54. *Biochem Biophys Res Commun.* 284: 1189-1193 (2001).

El-Ghundi M, **O'Dowd BF**, George SR: Prolonged fear responses in mice lacking dopamine D1 receptor. *Brain Res.* 892: 86-93 (2001).

Im DS, Heise CE, Nguyen T, **O'Dowd BF**, Lynch KR: Identification of a molecular target of psychosine and its role in globoid cell formation. *J Cell Biol.* 153: 429-434 (2001).

Lamey M, Thompson M, Varghese G, Chi H, Sawzdargo M, George SR, **O'Dowd BF**: Distinct residues in the carboxyl tail mediate agonist induced desensitization and internalization of the human dopamine D1 receptor. *J Biol Chem.* Dec 31 (2001).

Lee DK, George SR, Cheng R, Nguyen T, Liu Y, Brown M, Lynch KR, **O'Dowd BF**: Identification of four novel human G protein-coupled receptors expressed in the brain. *Brain Res Mol Brain Res*. 86: 13-22 (2001).

Lee DK, Nguyen T, Lynch KR, Cheng R, Vanti WB, Arkhitko O, Lewis T, Evans JF, George SR, **O'Dowd BF**: Discovery and mapping of ten novel G protein-coupled receptor genes. *Gene* 275: 83-91 (2001).

Lee DK, George SR, Evans JF, Lynch KR, **O'Dowd BF**: Orphan G protein-coupled receptors in the CNS. *Curr Opin Pharmacol*. 1: 31-39 (2001).

Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, **O'Dowd BF**: Discovery of a novel member of the histamine receptor family. *Mol Pharmacol*. 59: 427-433 (2001).

Ogilvie RI: The death of a volunteer research subject: lessons to be learned. *CMAJ* 165: 1335-1337 (2001).

Ogilvie RI: High-altitude illness. *N Engl J Med*. 345: 1279-1280 (2001).

Franc MA, Pohjanvirta R, Tuomisto J, **Okey AB**: Persistent, low-dose 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure: effect on aryl hydrocarbon receptor expression in a dioxin-resistance model. *Toxicol Appl Pharmacol*. 175: 43-53 (2001).

Franc MA, Pohjanvirta R, Tuomisto J, **Okey AB**: In vivo up-regulation of aryl hydrocarbon receptor expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in a dioxin-resistant rat model. *Biochem Pharmacol*. 62: 1565-1578 (2001).

Ozdemir V, Kalow W, **Okey AB**, Lam MS, Albers LJ, Reist C, Fourie J, Posner P, Collins EJ, Roy R: Treatment-resistance to clozapine in association with ultra rapid CYP1A2 activity and the C? A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. *J Clin Psychopharmacol*. 21: 603-607 (2001).

Wong JM, **Okey AB**, Harper PA: Human aryl hydrocarbon receptor polymorphisms that result in loss of CYP1A1 induction. *Biochem Biophys Res Commun*. 288: 990-996 (2001).

Wong JM, Harper PA, Meyer UA, Bock KW, Morike K, Lagueux J, Ayotte P, Tyndale RF, Sellers EM, Manchester DK, **Okey AB**: Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. *Pharmacogenetics* 11: 85-94 (2001).

"P,Q"

Reynaud D, Sun A, Demin P, **Pace-Asciak CR**: Improved HPLC method for the combined analysis of phospholipase, lipoxygenase and cyclooxygenase activities in human platelets using acetylated fluorescent anthracene (ADAM) esters. *J Chromatog B* 762: 175-180 (2001).

Reynaud D, Sun A, Demin P, **Pace-Asciak CR**: Novel platelet anti-aggregating substances. *BBRC* 284: 580-582 (2001).

Wang MM, Thomson M, Ali M., **Pace-Asciak CR**, Al-Hassan JM: Catfish gel extract increases vascular permeability in the rat skin. *Inflammopharmacology* 8: 397-403 (2001).

Cong D, Fong AK, Lee R, **Pang KS**: Absorption of benzoic acid in segmental regions of the vascularly perfused rat small intestine preparation. *Drug Metab Dispos.* 29: 1539-1547 (2001).

Schwab AJ, Tao L, Yoshimura T, Simard A, Barker F, **Pang KS**: Hepatic uptake and metabolism of benzoate: a multiple indicator dilution, perfused rat liver study. *Am J Physiol Gastrointest Liver Physiol.* 280: G1124-36 (2001).

Tan E, Lu T, **Pang KS**: Futile cycling of estrone sulfate and estrone in the recirculating perfused rat liver preparation. *J Pharmacol Exp Ther.* 297: 423-436 (2001).

Tan E, **Pang KS**: Sulfation is rate limiting in the futile cycling between estrone and estrone sulfate in enriched periportal and perivenous rat hepatocytes. *Drug Metab Dispos.* 29: 335-346 (2001).

"R"

Rachamin G. Use of Toxicological Data in Evaluating Chemical Safety. In: Cohrssen B, Powell CH, (eds). *Patty's Toxicology* . Vol 1, Chapter 10. John Wiley and Sons, New York. pp 381-414 (2001).

Comanor L, Minor J, Conjeevaram HS, **Roberts EA**, Alvarez F, Bern EM, Goyens P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Sokal EM: Impact of chronic hepatitis B disease and interferon alpha therapy on growth of children. *J Viral Hepat.* 8:139-147 (2001).

Jackson R, **Roberts EA**: Identification of neonatal liver failure and perinatal hemochromatosis in Canada. *Paediatr Child Health* 6:248-250 (2001).

Khalil M, Shariat-Panahi A, Tootle R, Ryder T, McCloskey P, **Roberts E**, Hodgson H, Selden C: Proliferation of human hepatocyte cells lines as cohesive spheroid colonies in alginate markedly upregulates both synthetic and detoxificatory liver function. *J Hepatol.* 34:68-77 (2001).

Natsheh S, **Roberts EA**, Ngan B, Chait P, Ng VL: Liver failure with marked hyperferritinemia: 'Ironing out' the differences. *Can J Gastroenterol.* 15:537-540 (2001).

Roberts EA: Nothing endures but change (Research News). *Pediatr Res.* 49:452 (2001).

Roberts EA: Wilson's disease. Pediatric Web (www.PediatricWeb.com) 2001; text: 2987 words. Sy SKB, Tang BK, Pastrakuljic A, **Roberts EA**, Kalow W: Detailed characterization of mathematically derived hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine. *Eur J Clin Pharmacol.* 57:377-386 (2001).

Yeung LTF, **Roberts EA**: Hepatitis B in Childhood? An Update for the Pediatrician. *Paediatr Child Health* 6:655-660 (2001).

Yeung LTF, King SM, **Roberts EA**: ("Concise Review") Mother-to-infant transmission of hepatitis C virus. *Hepatology* 34:223-229 (2001).

Katayama T, Imaizumi K, Honda A, Yoneda T, Kudo T, Takeda M, Mori K, Rozmahel R, Fraser P, George-Hyslop PS, Tohyama M: Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations. *J Biol Chem.* 276(46):43446-54 (2001).

"S"

Le T, **Schimmer BP**: The regulation of mitogen-activated protein kinases in Y1 mouse adrenocortical tumor cells. *Endocrinology* 142: 4282-4287 (2001).

Lopez D, Nackley AC, Shea-Eaton W, Xue I, **Schimmer BP**, McLean, MP: Effects of mutating different steroidogenic factor-1 protein regions on gene regulation. *Endocrine* 14: 353-362 (2001).

Parker KL, **Schimmer BP**: Pituitary hormones and their hypothalamic releasing factors. In: Hardman JG, Limbird LE (ed.), Goodman and Gilman's The Pharmacological Basis of Therapeutics. vol. 10 ed. New York, McGraw-Hill, Inc., pp. 1541-1562 (2001).

Parker KL, **Schimmer BP**: Steroidogenic factor-1. In: Creighton TE (ed.), *Encyclopedia of Molecular Medicine*. Vol. New York, John Wiley & Sons, Inc., pp. 3017- 3019 (2001).

Parker KL, **Schimmer BP**: Genetics of the development and function of the adrenal cortex. *Rev Endocr Metab Disorders* 2: 245-252 (2001).

Schimmer BP, Parker KL: Adrenocorticotrophic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE (ed.), *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. vol. 10 ed. New York, McGraw-Hill, Inc., pp. 1649-1677 (2001).

Binkely K, King N, Poonai N, **Seeman P**, Ulpian C, Kennedy J: Idiopathic Environmental Intolerance: Increased prevalence of panic-disorder-associated cholecystokinin B receptor allele 7. *J Allergy Clin Immunol*. 107: 887-890 (2001).

Kapur S, **Seeman P**: Does Fast Dissociation From the Dopamine D2 receptor Explain the Action of Atypical Antipsychotics? - A New Hypothesis. *Am J Psychiat*. 158 (3): 360-369 (2001).

Kapur S, **Seeman P**: Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor. *Biol Psychiat*. 49: 954-957 (2001).

Kapur S, **Seeman P**: Reply to Comment by J.H. Krystal and D.C. Dsouza on ³Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor.² *Biol Psychiat*. 50: 555 (2001).

Seeman P: Antipsychotic drugs, dopamine receptors, and schizophrenia. *Clin Neurosci Res*. 1: 53-60 (2001).

Seeman P, Kapur S: The dopamine receptor basis of psychosis. In: Breier A, Tran PV, Herrera J, Bymaster F, Tollefson G, (eds). *Current issues in the Psychopharmacology of Schizophrenia*. Lippincott Williams & Wilkins, Philadelphia, pp. 73-84 (2001).

Tallerico T, Novak G, Liu IS, Ulpian C, **Seeman P**: Schizophrenia: Elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. *Brain Res Mol Brain Res*. 87: 160-165 (2001).

Kilicarslan T, Haining RL, Rettie AE, Busto U, Tyndale RF, **Sellers EM**: Flunitrazepam metabolism by cytochrome P450s 2C19 and 3A4. *Drug Metab Dispos*. 29: 460-465 (2001).

Ramamoorthy Y, Tyndale RF, **Sellers EM**: Cytochrome P450 2D6*1 and cytochrome P450 2D6*10 differ in catalytic activity for multiple substrates. *Pharmacogenetics* 11: 477-487 (2001).

Tomkins DM, **Sellers EM**: Addiction and the brain: Role of neurotransmitters in aetiology and treatment. *Can Med Assoc J.* 164: 817-821 (2001).

Tyndale RF, **Sellers EM**: Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. *Drug Metab Dispos.* 29: 548-552 (2001).

von Moltke LL, Greenblatt DJ, Romach MK, **Sellers EM**: Cognitive toxicity of drugs used in the elderly. *Dialogues Clin Neurosci* 3:181-190 (2001).

Wong JMY, Harper PA, Meyer UA, Bock KW, Mörike K, Lagueux J, Ayotte P, Tyndale RF, **Sellers EM**, Manchester DK, Okey AB: Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function *in vitro*. *Pharmacogenetics* 11: 85-94 (2001).

Zhang W, Kilicarslan T, Tyndale R, **Sellers EM**: Evaluation of methoxsalen, tranlycypromine, and tryptamine as specific and selective CYP2A6 inhibitors *in vitro*. *Drug Metab Dispos.* 26: 897-902 (2001).

Crow AH, Song S, **Semple JW**, Freedman J and Lazarus AH: IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia (PIT) independent of anti-idiotypic reactivity. *Brit J Haematol.* 115: 679-686 (2001).

Semple JW: A novel mechanism of how leukocytes modulate allogeneic platelet immunity. In: Blajchman MA, Dzik S, Vamvakas EC, Sweeny J, Synder EL, (eds). *Clinical and Molecular Basis of Transfusion-Induced Immunomodulation: Summary of the proceedings of a state-of-the-art conference* . *Transfusion Med Rev.* 15:108-135 (2001).

Semple JW: Physiology of ITP. In: *Proceedings of the ITP Conference* . Platelet Disorder Support Association Press, Potomac, MD. pp 9-12 (2001).

Semple JW: Overview of Innate Immunity. In: *The Compendium* . AABB Press, Bethesda MD., p 15-21 (2001).

Fleischer Ir AB, Schwartzel EH, Colby SI, Altman DI and the Depigmenting Solution Study Group (incl. **Shear NH**): The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentiginos and related hyperpigmented lesions in two double-blind multicenter clinical studies. *J Am Acad Dermatol.* 42:459-67 (2001).

Gupta AK, Lambert I, Revuz I, **Shear NH**: Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. *Eur J Dermatol.* 11(1):6-10 (2001).

Katz GG, **Shear NH**, Malkiewicz IM, Valentino K, Neuman M: Signaling for ethanol- induced apoptosis and repair in vitro. *Clinical Biochem.* 34: 219-7 (2001).

Knowles S, Shapiro L, **Shear NH**: Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of "sulfa" allergy. *Drug Safety.* 24: 239- 47 (2001).

Liu BA, Knowles SR, Mittmann N, Einarson T, **Shear NH**: [Reporting of fatal adverse drug reactions.] *Can J Clin Pharmacol.* 8: 84-88 (2001).

Lowitt M, **Shear NH**: Pharmacogenomics and dermatological therapeutics. *Arch Dermatol.* 137: 1512- 4 (2001).

Neuman MG, Benhamou JP, Malkiewicz I, Akremi R, **Shear NH**, Asselah T, Ibrahim A, Boyer N, Marinot-Peignoux M, Iacobson-Brown P, Katz GG, Le Breton V, Le Guludec G, Suneja A, Marcellin P: Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. *Clin Biochem.* 34: 173-82 (2001).

Neuman MG, **Shear NH**, Iacobson-Brown P, Katz 00, Neilson HK, Malkiewicz IM, Cameron RO, Abbott F: CYP2E1-mediated modulation of valeric acid-induced Hepatotoxicity. *Clin Biochem.* 34: 211-8 (2001).

Neuman MG, Blendis LM, **Shear NH**, Malkiewicz IM, Ibrahim A, Katz 00, Sapir D, Halpem Z, Brill S, Peretz H, Magazinik S, Konikoff FM: Cytokine network in non- responding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate. *Clin Biochem.* 34: 183-8 (2001).

Neuman MG, Brenner DA, Rehermann B, Taieb J, Chollet-Martin S, Cohard M, Garaud JJ, Poynard T, Katz GG, Cameron RG, **Shear NH**, Gao B, Takamatsu M, Yamauchi M, Ohata M, Saito S, Maeyama S, Uchikoshi T, Toda G, Kumagi T, Akbar SM, Abe M, Michitaka K, Horiike N, Onji M: Mechanisms of alcoholic liver disease: Cytokines. *Alcohol Clin Exp Res.* 25(5 Suppl ISBRA): 251S-253S (2001).

Ozdemir V, **Shear NH**, Kalow W: Pharmacogenetics: What will be its role in evaluating drug safety and minimizing adverse effects? *Drug Safety.* 24: 75-85 (2001).

Papp K, Bissonnette R, Krueger IO, Carey W, Gatton D, Gulliver WP , Lai H, Lynde CW, Magen A, Mincer D, Ailed JP, Pater P, Shapiro I, **Shear NH**, Kramer S, Walicke P, Bauer R, Deddick RLL, Kim SS, White M, Garovoy M: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. *J Am Acad Dermatol.* 45: 667-74 (2001).

Popat A, **Shear NH**, Malkiewicz I, Stewart MI, Steenkamp V, Thomson S, Neuman MG: The toxicity of *Callilepis laureola*, a South African traditional herbal medicine. *Clin Biochem.* 34: 229-36 (2001).

Shapiro LE, Utrecht JP, **Shear NH**: Minocycline, perinuclear antibody and pigment. The biochemical basis. *J Am Acad Dermatol.* 45: 787-9 (2001).

Shear NH: The science of health technology assessment: The safety perspective. *Can J Clin Pharmacol.* 8 (Suppl A): 24A- 28A (2001).

Sullivan IR, **Shear NH**: The drug hypersensitivity syndrome: What is the pathogenesis? *Arch Dermatol.* 137: 357- 64 (2001).

Trakas K, Oh P, Singh S, Risebrough N, **Shear NH**: The health status of obese individuals in Canada. *Int J Obesity.* 25: 662- 668 (2001).

"T"

Ozdemir V, Kalow W, Posner P, Collins EJ, Kennedy JL, Tang BK, Albers LJ, Reist C, Roy R, Walkes W, Afra P: CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. *J Clin Psychopharmacol.* 21:398-407 (2001).

Sy SK, Tang BK, Pastrakuljic A, Roberts EA, Kalow W: Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine. *Eur J Clin Pharmacol.* 57:377-86 (2001)

Toal CB: Blood pressure control in patients with mild to moderate essential hypertension switched from nifedipine gastrointestinal therapeutic system (GITS) 30 mg to nifedipine GITS 20 mg. *Clin Ther.* 23:87-96 (2001).

Tomkins DM, Sellers EM: Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. *CMAJ.* 164:817-21 (2001).

Benowitz NL, **Tyndale RF**, Griffin C: Deficient C-oxidation of nicotine continued. *Clin Pharmacol Ther.* 70: 567 (2001).

Gaedigk A, Casley WL, **Tyndale RF**, Sellers EM, Jurima-Romet M, and Leeder JS: Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. *Can J Physiol Pharmacol.* 79: 841-847 (2001).

Howard L, Micu A, Sellers EM, Miksys S, **Tyndale RF**. Low doses of nicotine and ethanol induce CYP2E1 protein and chlorzoxazone metabolism in rat liver. *J Pharmacol. Exp Ther.* 299: 542-550 (2001).

Kalow W, Meyer UA, **Tyndale RF**: (eds.) Pharmacogenomics (Drugs and the Pharmaceutical Sciences series) , Marcel Dekker, Inc., (2001).

Kilicarslan T, Haining R, Rettie AE, Busto U, **Tyndale RF**, EM Sellers: Flunitrazepam metabolism by cytochromes P450 2C19 and 3A4. *Drug Metab Disp.* 29: 460-465 (2001).

Mash DC, Koverna CA, Pablo J, **Tyndale RF**, Ervin FD, Kamlet J, Hearn WL: Ibogaine in the treatment of heroin withdrawal. *Alkaloids Chem Biol.* 56:155-71 (2001).

Petrie J, Sapp DW, **Tyndale RF**, Kang M, Fanselow M, Olsen RW: Altered GABAA Receptor Subunit Expression in Rats Treated with Chronic Intermittent Ethanol (CIE). *Alcohol Clin Exp Res.* 25:819-28 (2001).

Ramamoorthy Y, **Tyndale RF**, Sellers EM: Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. *Pharmacogenetics* 11:477-87 (2001).

Schoedel KA, Sellers EM, **Tyndale RF**. Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. *Biochem Pharmacol.* 62: 1025-1036 (2001).

Tyndale RF, Schoedel KA, Mash DC, and Miksys S. Nicotine Metabolizing CYP2B6 In Human Brain: Higher Levels In Smokers. *Nicotine and Tobacco Res.* 3: 279 (2001).

Tyndale RF, Sellers EM: Variable CYP2A6-mediated nicotine metabolism alters smoking behavior. *Drug Metab Disp.* 29: 548-552 (2001).

Wong JMY, Harper PA, Meyer UA, Bock KW, Morike K, Lagueux J, Ayotte P, **Tyndale RF**, Sellers EM, Manchester DK, Okey AB: Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. *Pharmacogenetics* 11: 85-94 (2001).

Zhang W, Kilicarslan T, **Tyndale RF**, Sellers EM: Methoxsalen, tranilcypromine and tryptamine as specific and selective CYP2A6 inhibitors in vitro. *Drug Metab Disp.* 29: 897-902 (2001).

"U,V"

Guest I, **Utrecht J**. Bone marrow stem cell protection from chemotherapy by low-molecular weight compounds. *Exp Hematol*. 29: 123-137 (2001).

Iverson SL, **Utrecht JP**. Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. *Chem Res Toxicol*. 14, 175-181 (2001).

Sayeh E, **Utrecht JP**. Factors that Modify Penicillamine-Induced Autoimmunity in Brown Norway Rats: Failure of the Th1/Th2 Paradigm, *Toxicology* 163, 195-211 (2001).

Shapiro LE, **Utrecht J**, Shear NH: Minocycline, perinuclear cytoplasmic antibody, and pigment: the biochemical basis, *J Am Acad Dermatol* 45(5), 787-789 (2001).

Oak JN, Lavine N, **Van Tol HHM**: Dopamine D₄ and D_{2L} receptor stimulation of the mitogen-activated protein kinase pathway is dependent on *transactivation* of the PDGF receptor. *Mol Pharmacol*. 60: 92-103 (2001).

Oldenhof J, Ray A, Vickery R, **Van Tol HHM**: SH3 ligand in the dopamine D3 receptor. *Cellular Signaling* 13: 411-416 (2001).

Park, P, Sum CS, Hampson DR, **Van Tol HHM**, Wells JW: Nature of the oligomers formed by muscarinic m2 acetylcholine receptors in Sf9 cells. *Eur J Pharmacol*. 421: 11-22 (2001).

Wintle R, **Van Tol HHM**: Dopamine signalling in *C.elegans* - potential for parkinsonism research. *Parkinsonism and Related Disorders* 7: 177-183(2001).

"W"

Corson TW, Li PP, Kennedy JL, Macciardi F, Cooke RG, Parikh SV, **Warsh JJ**: Association analysis of G-protein beta 3 subunit gene with altered Ca(2+) homeostasis in bipolar disorder. *Mol Psychiat*. 6: 125-126 (2001).

Hua LV, Green M, **Warsh JJ**, Li PP: Molecular cloning of a novel isoform of diphosphoinositol polyphosphate phosphohydrolase: a potential target of lithium therapy. *Neuropsychopharmacology* 24: 640-651 (2001).

Hua LV, Green M, Wong A, **Warsh JJ**, Li PP: Tetraspan protein CD151: a common target of mood stabilizing drugs? *Neuropsychopharmacology* 25: 729-736 (2001).

Yoon IS, Li PP, Siu KP, Kennedy JL, Cooke RG, Parikh SV, **Warsh JJ**: Altered IMPA2 gene expression and calcium homeostasis in bipolar disorder. *Mol Psychiat*. 6: 678-683 (2001).

Yoon IS, Li PP, Siu KP, Kennedy JL, Macciardi F, Cooke RG, Parikh SV, **Warsh JJ**: Altered TRPC7 gene expression in bipolar-I disorder. *Biol Psychiatry* 50: 620-626 (2001).

Aleksa K, **Woodland C**, Koren G: Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies. *Pediatr Nephrol*. 16: 1153-1158 (2001).

Boskovic R, Klein J, **Woodland C**, Karaskov T, Koren G: The role of the placenta in variability of fetal exposure to cocaine and cannabinoids: a twin study. *Can J Physiol Pharmacol*.79: 942-945 (2001).

"X,Y,Z"

Zack M

Corrigall WA, **Zack M**, Eissenberg T, Belsito L, Scher R: Acute subjective and physiological responses to smoking in adolescents. *Addiction* 96: 1409-1417 (2001).

Zack M, Belsito L, Scher R, Eissenberg T, Corrigall WA: Effects of abstinence and smoking on information processing in adolescent smokers. *Psychopharmacol*. 153: 249-257 (2001).
